Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2

J Spratlin - Current oncology reports, 2011 - Springer
Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than
any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial …
被引用次数：109 相关文章

[引用][C] Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

J Spratlin - Current Oncology Reports, 2011 - cir.nii.ac.jp
Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth
Factor Receptor-2 | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2

J Spratlin - Current oncology reports, 2011 - pubmed.ncbi.nlm.nih.gov
Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than
any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial …

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.

J Spratlin - Current Oncology Reports, 2011 - europepmc.org
Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than
any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial …

Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

J Spratlin - Current Oncology Reports, 2011 - infona.pl
Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than
any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial …

[引用][C] Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

J Spratlin - Current Oncology Reports, 2011 - Springer